Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: A retrospective study of 221 cases from a single institution

Oncologist

Volumn 16, Issue 5, 2011, Pages 641-650

  Dai, Honghai ^a   Hui, Zhouguang ^a   Ji, Wei ^a   Liang, Jun ^a   Lu, Jima ^a   Ou, Guangfei ^a   Zhou, Zongmei ^a   Feng, Qinfu ^a   Xiao, Zefen ^a   Chen, Dongfu ^a   Zhang, Hongxing ^a   Yin, Weibo ^a   He, Jie ^a   Wang, Luhua ^a  

^a CANCER HOSPITAL   (China)

Author keywords

IIIA N2; Non small cell lung cancer; Postoperative radiotherapy; Surgery; Survival

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79956286590     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0343     Document Type: Review

References (28)

1. Vansteenkiste JF, De Leyn PP, Deneffe GJ et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: Analysis of the literature. Lung Cancer 1998;19:3-13.
2. Suzuki K, Nagai K, Yoshida J et al. The prognosis of surgically resected N2 non-small cell lung cancer: The importance of clinical N status. J Thorac Cardiovasc Surg 1999;118:145-153.
3. Kim KJ, Ahn YC, Lim do H et al. Analyses on prognostic factors following tri-modality therapy for stage III a non-small cell lung cancer. Lung Cancer 2007;55:329-336.
4. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-1049.
5. Casali C, Stefani A, Natali P et al. Prognostic factors in surgically resected N2 non-small cell lung cancer: The importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg 2005;28:33-38.
6. Andre F, Grunenwald D, Pignon JP et al. Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989.
7. Arriagada R, Bergman B, Dunant A et al.; International Adjuvant Lung cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
8. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352: 2589-2597.
9. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 2006;7: 719-727.
10. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in nonsmall-cell lung cancer: Systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-263.
11. Bekelman JE, Rosenzweig KE, Bach PB et al. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;66:492-499.
12. Uno T, Sumi M, Kihara A et al. Postoperative radiotherapy for non-smallcell lung cancer: Results of the 1999-2001 patterns of care study nationwide process survey in Japan. Lung Cancer 2007;56:357-362.
13. Lally BE, Zelterman D, Colasanto JM et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2006;24:2998-3006.
14. Douillard JY, Rosell R, De Lena M et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: The adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys 2008;72:695-701.
15. Munro AJ. What now for postoperative radiotherapy for lung cancer? Lancet 1998;352:250-251.
16. Zou B, Xu Y, Li T et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys 2010;77:321-328.
17. Moretti L, Yu DS, Chen H et al. Prognostic factors for resected non-small cell lung cancer with pN2 status: Implications for use of postoperative radiotherapy. The Oncologist 2009;14:1106-1115.
18. Bradley JD, Paulus R, Graham MV et al. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: Promising long-term results of the Radiation Therapy Oncology Group-RTOG 9705. J Clin Oncol 2005;23: 3480-3487.
19. Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986;315:1377-1381.
20. Stephens RJ, Girling DJ, Bleehen NM et al. The role of post-operative radiotherapy in non-small-cell lung cancer: A multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer 1996;74:632-639.
21. Feng QF, Wang M, Wang LJ et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: A randomized trial. Int J Radiat Oncol Biol Phys 2000;47:925-929.
22. Scotti V, Meattini I, Saieva C et al. Post-operative radiotherapy in N2 nonsmall cell lung cancer: A retrospective analysis of 175 patients. Radiother Oncol 2010;96:84-88.
23. Dautzenberg B, Arriagada R, Chammard AB et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Cancer 1999;86:265-273.
24. Bradley J, Graham MV, Winter K et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-328.
25. Keller SM, Adak S, Wagner H et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA nonsmall-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222.
26. Machtay M, Lee JH, Shrager JB et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001;19: 3912-3917.
27. Wakelee HA, Stephenson P, Keller SM et al. Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. Lung Cancer 2005;48:389-397.
28. Le Péchoux C, Dunant A, Pignon JP et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. J Clin Oncol 2007;25:e10-e11.